Adjunctive moxifloxacin in the treatment of generalized aggressive periodontitis patients: clinical and microbiological results of a randomized, triple-blind and placebo-controlled clinical trial

作者：Martin Ardila Carlos; Felipe Martelo Cadavid Juan; Boderth Acosta Gina; Adriana Ariza Garces Astrid; Guzman Isabel C

来源：Journal of Clinical Periodontology, 2015, 42(2): 160-168.

DOI：10.1111/jcpe.12345

• generalized aggressive periodontitis
• microbiology
• moxifloxacin
• periodontitis
• therapy
• randomized-controlled clinical trial

AimThe aim of the present study was to evaluate the clinical and microbiological efficacy of moxifloxacin (MOX) in one-stage scaling and root planing (SRP) in treating generalized aggressive periodontitis (GAgP).
Materials and MethodsForty subjects were randomly allocated to two treatment groups. The two treatment groups consisted of SRP combined with systemically admi-nistered MOX at the dosage of 400mg once daily for 7days or SRP+placebo once daily for 7days. Subgingival plaque samples were analysed for cultivable bacteria.
ResultsBoth groups resulted in significant reduction of probing depth (PD) and clinical attachment level (CAL) compared with baseline (p<0.0001), and this difference was maintained at 6months from baseline in both groups. However, subjects receiving MOX showed the greatest improvements CAL, and PD. Subjects in both groups at 6months displayed the greatest reduction from baseline in frequency of sites with PD 6mm (p<0.001), favouring the MOX group. Adjunctive antibiotic protocol reduced subgingival Aggregatibacter actinomycetemcomitans to undetectable levels, after 3 and 6months, and there was a significant reduction in the levels of Porphyromonas gingivalis and Tannerella forsythia in the MOX group compared to the placebo group.
ConclusionsThe results from this study suggest that moxifloxacin as and adjunct to one-stage full-mouth SRP leads to a better clinical and microbiological advantages compared to mechanical treatment.

• 出版日期2015-2